Oncogenic functions of the transcription factor Nrf2

Free Radical Biology and Medicine

Volumn 65, Issue , 2013, Pages 750-764

  Gañán Gómez, Irene ^a   Wei, Yue ^b   Yang, Hui ^b   Boyano Adánez, María Carmen ^a   García Manero, Guillermo ^b  

^a UNIVERSITY OF ALCALÁ   (Spain)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Apoptosis; Autophagy; Cancer; Cell growth; Chemoresistance; Cytoprotection; Electrophiles; Free radicals; Keap1; Mutation; Nrf2; Oxidative stress; Proto oncogene; Tumorigenesis

Indexed keywords

ABELSON KINASE; BREAKPOINT CLUSTER REGION PROTEIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; DOXYCYCLINE; ETOPOSIDE; HISTONE DEACETYLASE INHIBITOR; IDARUBICIN; KELCH LIKE ECH ASSOCIATED PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEASOME INHIBITOR; PROTEIN BCL 2; PROTEIN BCL XL; THIOREDOXIN REDUCTASE 1; TRANSCRIPTION FACTOR NRF2; UVOMORULIN; VORINOSTAT; NFE2L2 PROTEIN, HUMAN;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; AUTOPHAGY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CARCINOGENESIS; CELL FATE; CELL GROWTH; CELL PROLIFERATION; COLON CANCER; DNA DAMAGE; ENZYME ACTIVITY; EPIGENETICS; ESOPHAGUS CANCER; GENE MUTATION; HEAD AND NECK CANCER; HETEROZYGOSITY LOSS; HUMAN; IN VIVO STUDY; LIVER CANCER; LUNG NON SMALL CELL CANCER; METASTASIS; NONHUMAN; OVARY CANCER; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN METABOLISM; PROTEIN PROCESSING; PROTEIN STABILITY; PROTEIN SYNTHESIS; PROTO ONCOGENE; REVIEW; SIGNAL TRANSDUCTION; SKIN CANCER; STOMACH CANCER; TREATMENT RESPONSE; UBIQUITINATION; UPREGULATION; ANIMAL; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; NEOPLASMS; ONCOGENE; PATHOLOGY; PHYSIOLOGY;

ANIMALS; APOPTOSIS; CARCINOGENESIS; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASMS; NF-E2-RELATED FACTOR 2; ONCOGENES;

EID: 84883736109     PISSN: 08915849     EISSN: 18734596     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2013.06.041     Document Type: Review

References (204)

1. P. Moi, K. Chan, I. Asunis, A. Cao, and Y.W. Kan Isolation of NF-E2-related factor 2 (Nrf2), a NF-E2-like basic leucine zipper transcriptional activator that binds to the tandem NF-E2/AP1 repeat of the beta-globin locus control region Proc. Natl. Acad. Sci. USA 91 1994 9926 9930 (Pubitemid 24311921)
2. K. Itoh, N. Wakabayashi, Y. Katoh, T. Ishii, K. Igarashi, J.D. Engel, and M. Yamamoto Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain Genes Dev. 13 1999 76 86 (Pubitemid 29045117)
3. Y. Katoh, K. Iida, M.I. Kang, A. Kobayashi, M. Mizukami, K.I. Tong, M. McMahon, J.D. Hayes, K. Itoh, and M. Yamamoto Evolutionarily conserved N-terminal domain of Nrf2 is essential for the Keap1-mediated degradation of the protein by proteasome Arch. Biochem. Biophys. 433 2005 342 350 (Pubitemid 39592789)
4. S.B. Cullinan, J.D. Gordan, J. Jin, J.W. Harper, and J.A. Diehl The Keap1-BTB protein is an adaptor that bridges Nrf2 to a Cul3-based E3 ligase: oxidative stress sensing by a Cul3-Keap1 ligase Mol. Cell. Biol. 24 2004 8477 8486 (Pubitemid 39245070)
5. M. Furukawa, and Y. Xiong BTB protein Keap1 targets antioxidant transcription factor Nrf2 for ubiquitination by the cullin 3-Roc1 ligase Mol. Cell. Biol 25 2005 162 171 (Pubitemid 40039808)
6. K.I. Tong, Y. Katoh, H. Kusunoki, K. Itoh, T. Tanaka, and M. Yamamoto Keap1 recruits Neh2 through binding to ETGE and DLG motifs: characterization of the two-site molecular recognition model Mol. Cell. Biol. 26 2006 2887 2900
7. T. Nguyen, P.J. Sherratt, H.C. Huang, C.S. Yang, and C.B. Pickett Increased protein stability as a mechanism that enhances Nrf2-mediated transcriptional activation of the antioxidant response element: degradation of Nrf2 by the 26 S proteasome J. Biol. Chem. 278 2003 4536 4541 (Pubitemid 36800950)
8. A. Kobayashi, M.I. Kang, H. Okawa, M. Ohtsuji, Y. Zenke, T. Chiba, K. Igarashi, and M. Yamamoto Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2 Mol. Cell. Biol. 24 2004 7130 7139 (Pubitemid 39014439)
9. W. Li, and A.N. Kong Molecular mechanisms of Nrf2-mediated antioxidant response Mol. Carcinog. 48 2009 91 104
10. K. Taguchi, H. Motohashi, and M. Yamamoto Molecular mechanisms of the Keap1-Nrf2 pathway in stress response and cancer evolution Genes Cells 16 2011 123 140
11. A. Kobayashi, M.I. Kang, Y. Watai, K.I. Tong, T. Shibata, K. Uchida, and M. Yamamoto Oxidative and electrophilic stresses activate Nrf2 through inhibition of ubiquitination activity of Keap1 Mol. Cell. Biol. 26 2006 221 229
12. G. Rachakonda, Y. Xiong, K.R. Sekhar, S.L. Stamer, D.C. Liebler, and M.L. Freeman Covalent modification at Cys151 dissociates the electrophile sensor Keap1 from the ubiquitin ligase CUL3 Chem. Res. Toxicol. 21 2008 705 710 (Pubitemid 351498046)
13. K. Itoh, N. Wakabayashi, Y. Katoh, T. Ishii, T. O'Connor, and M. Yamamoto Keap1 regulates both cytoplasmic-nuclear shuttling and degradation of Nrf2 in response to electrophiles Genes Cells 8 2003 379 391 (Pubitemid 36504013)
14. M. McMahon, K. Itoh, M. Yamamoto, and J.D. Hayes Keap1-dependent proteasomal degradation of transcription factor Nrf2 contributes to the negative regulation of antioxidant response element-driven gene expression J. Biol. Chem 278 2003 21592 21600 (Pubitemid 36792558)
15. K. Itoh, T. Chiba, S. Takahashi, T. Ishii, K. Igarashi, Y. Katoh, T. Oyake, N. Hayashi, K. Satoh, I. Hatayama, M. Yamamoto, and Y. Nabeshima An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements Biochem. Biophys. Res. Commun. 236 1997 313 322 (Pubitemid 27373291)
16. J. Alam, D. Stewart, C. Touchard, S. Boinapally, A.M. Choi, and J.L. Cook Nrf2, a cap'n'collar transcription factor, regulates induction of the heme oxygenase-1 gene J. Biol. Chem. 274 1999 26071 26078
17. R. Venugopal, and A.K. Jaiswal Nrf1 and Nrf2 positively and c-fos and Fra1 negatively regulate the human antioxidant response element-mediated expression of NAD(P)H:quinone oxidoreductase 1 gene Proc. Natl. Acad. Sci. USA 93 1996 14960 14965 (Pubitemid 26419078)
18. M. McMahon, K. Itoh, M. Yamamoto, S.A. Chanas, C.J. Henderson, L.I. McLellan, C.R. Wolf, C. Cavin, and J.D. Hayes The cap'n'collar basic leucine zipper transcription factor Nrf2 (NF-E2 p45-related factor 2) controls both constitutive and inducible expression of intestinal detoxification and glutathione biosynthetic enzymes Cancer Res. 61 2001 3299 3307 (Pubitemid 32695017)
19. A.C. Wild, H.R. Moinova, and R.T. Mulcahy Regulation of gamma-glutamylcysteine synthetase subunit gene expression by the transcription factor Nrf2 J. Biol. Chem. 274 1999 33627 33636 (Pubitemid 129511675)
20. A. Banning, S. Deubel, D. Kluth, Z. Zhou, and R. Brigelius-Flohe The GI-GPx gene is a target for Nrf2 Mol. Cell. Biol. 25 2005 4914 4923 (Pubitemid 40781093)
21. K.J. Hintze, K.A. Wald, H. Zeng, E.H. Jeffery, and J.W. Finley Thioredoxin reductase in human hepatoma cells is transcriptionally regulated by sulforaphane and other electrophiles via an antioxidant response element J. Nutr. 133 2003 2721 2727 (Pubitemid 37099751)
22. J. Zhang, V. Svehlikova, Y. Bao, A.F. Howie, G.J. Beckett, and G. Williamson Synergy between sulforaphane and selenium in the induction of thioredoxin reductase 1 requires both transcriptional and translational modulation Carcinogenesis 24 2003 497 503 (Pubitemid 36432646)
23. Y.J. Kim, J.Y. Ahn, P. Liang, C. Ip, Y. Zhang, and Y.M. Park Human prx1 gene is a target of Nrf2 and is up-regulated by hypoxia/reoxygenation: implication to tumor biology Cancer Res. 67 2007 546 554 (Pubitemid 46192191)
24. K. Maeda, T. Ohno, S. Igarashi, T. Yoshimura, K. Yamashiro, and M. Sakai Aldehyde oxidase 1 gene is regulated by Nrf2 pathway Gene 505 2012 374 378
25. R.K. Thimmulappa, K.H. Mai, S. Srisuma, T.W. Kensler, M. Yamamoto, and S. Biswal Identification of Nrf2-regulated genes induced by the chemopreventive agent sulforaphane by oligonucleotide microarray Cancer Res. 62 2002 5196 5203 (Pubitemid 35033454)
26. A. Hayashi, H. Suzuki, K. Itoh, M. Yamamoto, and Y. Sugiyama Transcription factor Nrf2 is required for the constitutive and inducible expression of multidrug resistance-associated protein 1 in mouse embryo fibroblasts Biochem. Biophys. Res. Commun. 310 2003 824 829 (Pubitemid 37188696)
27. V. Vollrath, A.M. Wielandt, M. Iruretagoyena, and J. Chianale Role of Nrf2 in the regulation of the Mrp2 (ABCC2) gene Biochem. J. 395 2006 599 609
28. K. Okada, J. Shoda, K. Taguchi, J.M. Maher, K. Ishizaki, Y. Inoue, M. Ohtsuki, N. Goto, K. Takeda, H. Utsunomiya, K. Oda, E. Warabi, T. Ishii, K. Osaka, I. Hyodo, and M. Yamamoto Ursodeoxycholic acid stimulates Nrf2-mediated hepatocellular transport, detoxification, and antioxidative stress systems in mice Am. J. Physiol. Gastrointest. Liver Physiol. 295 2008 G735 47
29. K.C. Wu, J.Y. Cui, and C.D. Klaassen Effect of graded Nrf2 activation on phase-I and -II drug metabolizing enzymes and transporters in mouse liver PLoS One 7 2012 e39006
30. J.D. Hayes, M. McMahon, S. Chowdhry, and A.T. Dinkova-Kostova Cancer chemoprevention mechanisms mediated through the Keap1-Nrf2 pathway Antioxid. Redox Signaling 13 2010 1713 1748
31. S. Magesh, Y. Chen, and L. Hu Small molecule modulators of Keap1-Nrf2-ARE pathway as potential preventive and therapeutic agents Med. Res. Rev. 32 2012 687 726
32. U.S. National Institutes of Health. Clinical trial database: accessed December 2012.
33. U.S. National Center for Biotechnology Information. PubMed: accessed December 2012.
34. M. Ramos-Gomez, M.K. Kwak, P.M. Dolan, K. Itoh, M. Yamamoto, P. Talalay, and T.W. Kensler Sensitivity to carcinogenesis is increased and chemoprotective efficacy of enzyme inducers is lost in nrf2 transcription factor-deficient mice Proc. Natl. Acad. Sci. USA 98 2001 3410 3415 (Pubitemid 32220859)
35. K. Iida, K. Itoh, Y. Kumagai, R. Oyasu, K. Hattori, K. Kawai, T. Shimazui, H. Akaza, and M. Yamamoto Nrf2 is essential for the chemopreventive efficacy of oltipraz against urinary bladder carcinogenesis Cancer Res. 64 2004 6424 6431 (Pubitemid 39297896)
36. H. Satoh, T. Moriguchi, K. Taguchi, J. Takai, J.M. Maher, T. Suzuki, P.T. Winnard Jr, V. Raman, M. Ebina, T. Nukiwa, and M. Yamamoto Nrf2-deficiency creates a responsive microenvironment for metastasis to the lung Carcinogenesis 31 2010 1833 1843
37. G. Rachakonda, K.R. Sekhar, D. Jowhar, P.C. Samson, J.P. Wikswo, R.D. Beauchamp, P.K. Datta, and M.L. Freeman Increased cell migration and plasticity in Nrf2-deficient cancer cell lines Oncogene 29 2010 3703 3714
38. M.B. Sporn, and K.T. Liby NRF2 and cancer: the good, the bad and the importance of context Nat. Rev. Cancer 12 2012 564 571
39. K. Chan, and Y.W. Kan Nrf2 is essential for protection against acute pulmonary injury in mice Proc. Natl. Acad. Sci. USA 96 1999 12731 12736 (Pubitemid 29513571)
40. A. Enomoto, K. Itoh, E. Nagayoshi, J. Haruta, T. Kimura, T. O'Connor, T. Harada, and M. Yamamoto High sensitivity of Nrf2 knockout mice to acetaminophen hepatotoxicity associated with decreased expression of ARE-regulated drug metabolizing enzymes and antioxidant genes Toxicol. Sci. 59 2001 169 177 (Pubitemid 32117993)
41. K. Yoh, K. Itoh, A. Enomoto, A. Hirayama, N. Yamaguchi, M. Kobayashi, N. Morito, A. Koyama, M. Yamamoto, and S. Takahashi Nrf2-deficient female mice develop lupus-like autoimmune nephritis Kidney Int. 60 2001 1343 1353 (Pubitemid 32960028)
42. P. Shelton, and A.K. Jaiswal The transcription factor NF-E2-related factor 2 (Nrf2): a protooncogene? FASEB J 27 2013 414 423
43. H.L. Kim, and Y.R. Seo Molecular and genomic approach for understanding the gene-environment interaction between Nrf2 deficiency and carcinogenic nickel-induced DNA damage Oncol. Rep 28 2012 1959 1967
44. D. Sinha, J. Biswas, and A. Bishayee Nrf2-mediated redox signaling in arsenic carcinogenesis: a review Arch. Toxicol. 87 2013 383 396
45. B. Yang, J. Fu, H. Zheng, P. Xue, K. Yarborough, C.G. Woods, Y. Hou, Q. Zhang, and M.E. Andersen Pi, J. Deficiency in the nuclear factor E2-related factor 2 renders pancreatic β-cells vulnerable to arsenic-induced cell damage Toxicol. Appl. Pharmacol. 264 2012 315 323
46. Cheung, K. L.; Lee, J. H.; Khor, T. O.; Wu, T. Y.; Li, G. X.; Chan, J.; Yang, C. S.; Kong, A. N. Nrf2 knockout enhances intestinal tumorigenesis in Apc(min/+) mice due to attenuation of anti-oxidative stress pathway while potentiates inflammation. Mol. Carcinog. (in press). 10.1002/mc.21950
47. M.J. De Long, H.J. Prochaska, and P. Talalay Tissue-specific induction patterns of cancer-protective enzymes in mice by tert-butyl-4-hydroxyanisole and related substituted phenols Cancer Res 45 1985 546 551 (Pubitemid 15161043)
48. C.J. Powell, J.C. Connelly, S.M. Jones, P. Grasso, and J.W. Bridges Hepatic responses to the administration of high doses of BHT to the rat: their relevance to hepatocarcinogenicity Food Chem. Toxicol. 24 1986 1131 1143 (Pubitemid 17205319)
49. L. Zhang, N. Wang, S. Zhou, W. Ye, G. Jing, and M. Zhang Propofol induces proliferation and invasion of gallbladder cancer cells through activation of Nrf2 J. Exp. Clin. Cancer Res. 31 2012 66
50. E. Hara, K. Takahashi, T. Tominaga, T. Kumabe, T. Kayama, H. Suzuki, H. Fujita, T. Yoshimoto, K. Shirato, and S. Shibahara Expression of heme oxygenase and inducible nitric oxide synthase mRNA in human brain tumors Biochem. Biophys. Res. Commun. 224 1996 153 158 (Pubitemid 26252426)
51. M.D. Maines, and P.A. Abrahamsson Expression of heme oxygenase-1 (HSP32) in human prostate: normal, hyperplastic, and tumor tissue distribution Urology 47 1996 727 733 (Pubitemid 26172743)
52. A.I. Goodman, M. Choudhury, J.L. da Silva, M.L. Schwartzman, and N.G. Abraham Overexpression of the heme oxygenase gene in renal cell carcinoma Proc. Soc. Exp. Biol. Med. 214 1997 54 61
53. M. Sunamura, D.G. Duda, M.H. Ghattas, L. Lozonschi, F. Motoi, J. Yamauchi, S. Matsuno, S. Shibahara, and N.G. Abraham Heme oxygenase-1 accelerates tumor angiogenesis of human pancreatic cancer Angiogenesis 6 2003 15 24 (Pubitemid 37305335)
54. Y. Li, J. Su, X. DingZhang, J. Zhang, M. Yoshimoto, S. Liu, K. Bijian, A. Gupta, J.A. Squire, M.A. Alaoui Jamali, and T.A. Bismar PTEN deletion and heme oxygenase-1 overexpression cooperate in prostate cancer progression and are associated with adverse clinical outcome J. Pathol. 224 2011 90 100
55. J. Li, C. Yen, D. Liaw, K. Podsypanina, S. Bose, S.I. Wang, J. Puc, C. Miliaresis, L. Rodgers, R. McCombie, S.H. Bigner, B.C. Giovanella, M. Ittmann, B. Tycko, H. Hibshoosh, M.H. Wigler, and R. Parsons PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer Science 275 1997 1943 1947 (Pubitemid 27148818)
56. M. Mayerhofer, S. Florian, M.T. Krauth, K.J. Aichberger, M. Bilban, R. Marculescu, D. Printz, G. Fritsch, O. Wagner, E. Selzer, W.R. Sperr, P. Valent, and C. Sillaber Identification of heme oxygenase-1 as a novel BCR/ABL-dependent survival factor in chronic myeloid leukemia Cancer Res. 64 2004 3148 3154 (Pubitemid 38581416)
57. M.M. Singh, M.E. Irwin, Y. Gao, K. Ban, P. Shi, R.B. Arlinghaus, H.M. Amin, and J. Chandra Inhibition of the NADPH oxidase regulates heme oxygenase 1 expression in chronic myeloid leukemia Cancer 118 2012 3433 3445
58. J.J. Schlager, and G. Powis Cytosolic NAD(P)H: (quinone-acceptor) oxidoreductase in human normal and tumor tissue: effects of cigarette smoking and alcohol Int. J. Cancer 45 1990 403 409 (Pubitemid 20087182)
59. T. Cresteil, and A.K. Jaiswal High levels of expression of the NAD(P)H:quinone oxidoreductase (NQO1) gene in tumor cells compared to normal cells of the same origin Biochem. Pharmacol 42 1991 1021 1027
60. A. Marin, A. Lopez de Cerain, E. Hamilton, A.D. Lewis, J.M. Martinez-Penuela, M.A. Idoate, and J Bello DT-diaphorase and cytochrome B5 reductase in human lung and breast tumours Br. J. Cancer 76 1997 923 929 (Pubitemid 27401945)
61. A.M. Malkinson, D. Siegel, G.L. Forrest, A.F. Gazdar, H.K. Oie, D.C. Chan, P.A. Bunn, M. Mabry, D.J. Dykes, and S.D. Harrison Elevated DT-diaphorase activity and messenger RNA content in human non-small cell lung carcinoma: relationship to the response of lung tumor xenografts to mitomycin Cl Cancer Res. 52 1992 4752 4757
62. A.T. Dinkova-Kostova, and P. Talalay NAD(P)H:quinone acceptor oxidoreductase 1 (NQO1), a multifunctional antioxidant enzyme and exceptionally versatile cytoprotector Arch. Biochem. Biophys. 501 2010 116 123
63. C.M. Cabello, and W.B. Bair 3rd; Bause, A. S.; Wondrak, G. T. Antimelanoma activity of the redox dye DCPIP (2,6-dichlorophenolindophenol) is antagonized by NQO1 Biochem. Pharmacol. 78 2009 344 354
64. M. Garate, A.A. Wani, and G. Li The NAD(P)H:quinone oxidoreductase 1 induces cell cycle progression and proliferation of melanoma cells Free Radic. Biol. Med. 48 2010 1601 1609
65. M.M. Montano, N.R. Bianco, H. Deng, B.M. Wittmann, L.C. Chaplin, and B.S. Katzenellenbogen Estrogen receptor regulation of quinone reductase in breast cancer: implications for estrogen-induced breast tumor growth and therapeutic uses of tamoxifen Front. Biosci. 10 2005 1440 1461
66. M. Jamshidi, J. Bartkova, D. Greco, J. Tommiska, R. Fagerholm, K. Aittomaki, J. Mattson, K. Villman, R. Vrtel, J. Lukas, P. Heikkila, C. Blomqvist, J. Bartek, and H. Nevanlinna NQO1 expression correlates inversely with NFkappaB activation in human breast cancer Breast Cancer Res. Treat. 132 2012 955 968
67. D.T. Lincoln, E.M. Ali Emadi, K.F. Tonissen, and F.M. Clarke The thioredoxin-thioredoxin reductase system: over-expression in human cancer Anticancer Res. 23 2003 2425 2433 (Pubitemid 36897112)
68. L. Gan, X.L. Yang, Q. Liu, and H.B. Xu Inhibitory effects of thioredoxin reductase antisense RNA on the growth of human hepatocellular carcinoma cells J. Cell. Biochem. 96 2005 653 664 (Pubitemid 41504662)
69. M.H. Yoo, X.M. Xu, B.A. Carlson, V.N. Gladyshev, and D.L. Hatfield Thioredoxin reductase 1 deficiency reverses tumor phenotype and tumorigenicity of lung carcinoma cells J. Biol. Chem. 281 2006 13005 13008 (Pubitemid 43855208)
70. C. Kodate, A. Fukushi, T. Narita, H. Kudo, Y. Soma, and K. Sato Human placental form of glutathione S-transferase (GST-pi) as a new immunohistochemical marker for human colonic carcinoma Jpn. J. Cancer Res. 77 1986 226 229 (Pubitemid 16101922)
71. Y. Niitsu, Y. Takahashi, T. Saito, Y. Hirata, N. Arisato, H. Maruyama, Y. Kohgo, and I. Listowsky Serum glutathione-S-transferase-pi as a tumor marker for gastrointestinal malignancies Cancer 63 1989 317 323 (Pubitemid 19035025)
72. A.F. Howie, J.G. Douglas, R.J. Fergusson, and G.J. Beckett Measurement of glutathione S-transferase pi isoenzyme in plasma, a possible marker for adenocarcinoma of the lung Clin. Chem. 36 1990 453 456
73. Y. Shiratori, Y. Soma, H. Maruyama, S. Sato, A. Takano, and K. Sato Immunohistochemical detection of the placental form of glutathione S-transferase in dysplastic and neoplastic human uterine cervix lesions Cancer Res. 47 1987 6806 6809 (Pubitemid 18019688)
74. S. Hirata, T. Odajima, G. Kohama, S. Ishigaki, and Y. Niitsu Significance of glutathione S-transferase-pi as a tumor marker in patients with oral cancer Cancer 70 1992 2381 2387
75. K. Miyanishi, T. Takayama, M. Ohi, T. Hayashi, A. Nobuoka, T. Nakajima, R. Takimoto, K. Kogawa, J. Kato, S. Sakamaki, and Y. Niitsu Glutathione S-transferase-pi overexpression is closely associated with K-ras mutation during human colon carcinogenesis Gastroenterology 121 2001 865 874 (Pubitemid 32959396)
76. G.M. DeNicola, F.A. Karreth, T.J. Humpton, A. Gopinathan, C. Wei, K. Frese, D. Mangal, K.H. Yu, C.J. Yeo, E.S. Calhoun, F. Scrimieri, J.M. Winter, R.H. Hruban, C. Iacobuzio-Donahue, S.E. Kern, I.A. Blair, and D.A. Tuveson Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis Nature 475 2011 106 109
77. Y. Mitsuishi, K. Taguchi, Y. Kawatani, T. Shibata, T. Nukiwa, H. Aburatani, M. Yamamoto, and H. Motohashi Nrf2 redirects glucose and glutamine into anabolic pathways in metabolic reprogramming Cancer Cell 22 2012 66 79
78. N.M. Reddy, S.R. Kleeberger, M. Yamamoto, T.W. Kensler, C. Scollick, S. Biswal, and S.P. Reddy Genetic dissection of the Nrf2-dependent redox signaling-regulated transcriptional programs of cell proliferation and cytoprotection Physiol. Genomics 32 2007 74 81
79. D. Malhotra, E. Portales-Casamar, A. Singh, S. Srivastava, D. Arenillas, C. Happel, C. Shyr, N. Wakabayashi, T.W. Kensler, W.W. Wasserman, and S. Biswal Global mapping of binding sites for Nrf2 identifies novel targets in cell survival response through ChIP-seq profiling and network analysis Nucleic Acids Res. 38 2010 5718 5734
80. T. Shibata, S. Saito, A. Kokubu, T. Suzuki, M. Yamamoto, and S. Hirohashi Global downstream pathway analysis reveals a dependence of oncogenic NF-E2-related factor 2 mutation on the mTOR growth signaling pathway Cancer Res 70 2010 9095 9105
81. T. Yamadori, Y. Ishii, S. Homma, Y. Morishima, K. Kurishima, K. Itoh, M. Yamamoto, Y. Minami, M. Noguchi, and N. Hizawa Molecular mechanisms for the regulation of Nrf2-mediated cell proliferation in non-small-cell lung cancers Oncogene 31 2012 4768 4777
82. R.J. DeBerardinis, J.J. Lum, G. Hatzivassiliou, and C.B. Thompson The biology of cancer: metabolic reprogramming fuels cell growth and proliferation Cell Metab. 7 2008 11 20
83. M.S. Yates, Q.T. Tran, P.M. Dolan, W.O. Osburn, S. Shin, C.C. McCulloch, J.B. Silkworth, K. Taguchi, M. Yamamoto, C.R. Williams, K.T. Liby, M.B. Sporn, T.R. Sutter, and T.W. Kensler Genetic versus chemoprotective activation of Nrf2 signaling: overlapping yet distinct gene expression profiles between Keap1 knockout and triterpenoid-treated mice Carcinogenesis 30 2009 1024 1031
84. N.R. Kitteringham, A. Abdullah, J. Walsh, L. Randle, R.E. Jenkins, R. Sison, C.E. Goldring, H. Powell, C. Sanderson, S. Williams, L. Higgins, M. Yamamoto, J. Hayes, and B.K. Park Proteomic analysis of Nrf2 deficient transgenic mice reveals cellular defence and lipid metabolism as primary Nrf2-dependent pathways in the liver J. Proteomics 73 2010 1612 1631
85. W.D. Kim, Y.W. Kim, I.J. Cho, C.H. Lee, and S.G. Kim E-cadherin inhibits nuclear accumulation of Nrf2: implications for chemoresistance of cancer cells J. Cell. Sci. 125 2012 1284 1295
86. X. Tian, Z. Liu, B. Niu, J. Zhang, T.K. Tan, S.R. Lee, Y. Zhao, D.C. Harris, and G. Zheng E-cadherin/beta-catenin complex and the epithelial barrier J. Biomed. Biotechnol. 2011 2011 567305
87. J.M. Brown, and L.D. Attardi The role of apoptosis in cancer development and treatment response Nat. Rev. Cancer 5 2005 231 237 (Pubitemid 40314954)
88. K. Polyak, Y. Xia, J.L. Zweier, K.W. Kinzler, and B. Vogelstein A model for p53-induced apoptosis Nature 389 1997 300 305 (Pubitemid 27406646)
89. R. Faraonio, P. Vergara, D. Di Marzo, M.G. Pierantoni, M. Napolitano, T. Russo, and F. Cimino p53 suppresses the Nrf2-dependent transcription of antioxidant response genes J. Biol. Chem. 281 2006 39776 39784 (Pubitemid 46041781)
90. K. Iida, K. Itoh, J.M. Maher, Y. Kumagai, R. Oyasu, Y. Mori, T. Shimazui, H. Akaza, and M. Yamamoto Nrf2 and p53 cooperatively protect against BBN-induced urinary bladder carcinogenesis Carcinogenesis 28 2007 2398 2403 (Pubitemid 350111600)
91. W.S. el-Deiry, T. Tokino, V.E. Velculescu, D.B. Levy, R. Parsons, J.M. Trent, D. Lin, W.E. Mercer, K.W. Kinzler, and B. Vogelstein WAF1, a potential mediator of p53 tumor suppression Cell 75 1993 817 825 (Pubitemid 23346378)
92. W. Chen, T. Jiang, H. Wang, S. Tao, A. Lau, D. Fang, and D.D. Zhang Does Nrf2 contribute to p53-mediated control of cell survival and death? Antioxid. Redox Signaling 17 2012 1670 1675
93. E. Kalo, I. Kogan-Sakin, H. Solomon, E. Bar-Nathan, M. Shay, Y. Shetzer, E. Dekel, N. Goldfinger, Y. Buganim, P. Stambolsky, I. Goldstein, S. Madar, and V. Rotter Mutant p53R273H attenuates the expression of phase 2 detoxifying enzymes and promotes the survival of cells with high levels of reactive oxygen species J. Cell Sci. 125 2012 5578 5586
94. G. Filomeni, S. Piccirillo, G. Rotilio, and M.R. Ciriolo p38(MAPK) and ERK1/2 dictate cell death/survival response to different pro-oxidant stimuli via p53 and Nrf2 in neuroblastoma cells SH-SY5Y Biochem. Pharmacol 83 2012 1349 1357
95. S.K. Niture, and A.K. Jaiswal INrf2 (Keap1) targets bcl-2 degradation and controls cellular apoptosis Cell Death Differ. 18 2011 439 451
96. Q. Chen, W. Li, Y. Wan, X. Xia, Q. Wu, Y. Chen, Z. Lai, C. Yu, and W. Li Amplified in breast cancer 1 enhances human cholangiocarcinoma growth and chemoresistance by simultaneous activation of akt and Nrf2 pathways Hepatology 55 2012 1820 1829
97. S.K. Niture, and A.K. Jaiswal Nrf2 protein up-regulates antiapoptotic protein bcl-2 and prevents cellular apoptosis J. Biol. Chem. 287 2012 9873 9886
98. X.M. Yin, Z.N. Oltvai, and S.J. Korsmeyer BH1 and BH2 domains of bcl-2 are required for inhibition of apoptosis and heterodimerization with bax Nature 369 1994 321 323 (Pubitemid 24159542)
99. S.K. Niture, and A.K. Jaiswal Nrf2-induced antiapoptotic bcl-xL protein enhances cell survival and drug resistance Free Radic. Biol. Med. 57 2012 119 131
100. D.F. Lee, H.P. Kuo, M. Liu, C.K. Chou, W. Xia, Y. Du, J. Shen, C.T. Chen, L. Huo, M.C. Hsu, C.W. Li, Q. Ding, T.L. Liao, C.C. Lai, A.C. Lin, Y.H. Chang, S.F. Tsai, L.Y. Li, and M.C. Hung KEAP1 E3 ligase-mediated downregulation of NF-kappaB signaling by targeting IKKbeta Mol. Cell 36 2009 131 140
101. M.C. Hu, D.F. Lee, W. Xia, L.S. Golfman, F. Ou-Yang, J.Y. Yang, Y. Zou, S. Bao, N. Hanada, H. Saso, R. Kobayashi, and M.C. Hung IkappaB kinase promotes tumorigenesis through inhibition of forkhead FOXO3a Cell 117 2004 225 237 (Pubitemid 38496242)
102. D.F. Lee, H.P. Kuo, C.T. Chen, J.M. Hsu, C.K. Chou, Y. Wei, H.L. Sun, L.Y. Li, B. Ping, W.C. Huang, X. He, J.Y. Hung, C.C. Lai, Q. Ding, J.L. Su, J.Y. Yang, A.A. Sahin, G.N. Hortobagyi, F.J. Tsai, C.H. Tsai, and M.C. Hung IKK beta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway Cell 130 2007 440 455 (Pubitemid 47198298)
103. S.A. Rushworth, and D.J. MacEwan HO-1 underlies resistance of AML cells to TNF-induced apoptosis Blood 111 2008 3793 3801
104. M. Mayerhofer, K.V. Gleixner, J. Mayerhofer, G. Hoermann, E. Jaeger, K.J. Aichberger, R.G. Ott, K. Greish, H. Nakamura, S. Derdak, P. Samorapoompichit, W.F. Pickl, V. Sexl, H. Esterbauer, I. Schwarzinger, C. Sillaber, H. Maeda, and P. Valent Targeting of heat shock protein 32 (Hsp32)/heme oxygenase-1 (HO-1) in leukemic cells in chronic myeloid leukemia: a novel approach to overcome resistance against imatinib Blood 111 2008 2200 2210 (Pubitemid 351451534)
105. S.A. Rushworth, K.M. Bowles, P. Raninga, and D.J. MacEwan NF-kappaB-inhibited acute myeloid leukemia cells are rescued from apoptosis by heme oxygenase-1 induction Cancer Res. 70 2010 2973 2983
106. S.A. Heasman, L. Zaitseva, K.M. Bowles, S.A. Rushworth, and D.J. Macewan Protection of acute myeloid leukaemia cells from apoptosis induced by front-line chemotherapeutics is mediated by haem oxygenase-1 Oncotarget 2 2011 658 668
107. N. Ban, Y. Takahashi, T. Takayama, T. Kura, T. Katahira, S. Sakamaki, and Y. Niitsu Transfection of glutathione S-transferase (GST)-pi antisense complementary DNA increases the sensitivity of a colon cancer cell line to adriamycin, cisplatin, melphalan, and etoposide Cancer Res. 56 1996 3577 3582 (Pubitemid 26251655)
108. K.J. Cullen, K.A. Newkirk, L.M. Schumaker, N. Aldosari, J.D. Rone, and B.R. Haddad Glutathione S-transferase pi amplification is associated with cisplatin resistance in head and neck squamous cell carcinoma cell lines and primary tumors Cancer Res. 63 2003 8097 8102 (Pubitemid 37549452)
109. A. Singh, V. Misra, R.K. Thimmulappa, H. Lee, S. Ames, M.O. Hoque, J.G. Herman, S.B. Baylin, D. Sidransky, E. Gabrielson, M.V. Brock, and S. Biswal Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer PLoS Med. 3 2006 e420
110. T. Shibata, A. Kokubu, M. Gotoh, H. Ojima, T. Ohta, M. Yamamoto, and S. Hirohashi Genetic alteration of Keap1 confers constitutive Nrf2 activation and resistance to chemotherapy in gallbladder cancer Gastroenterology 135 2008 1358 1368
111. T. Shibata, T. Ohta, K.I. Tong, A. Kokubu, R. Odogawa, K. Tsuta, H. Asamura, M. Yamamoto, and S. Hirohashi Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy Proc. Natl. Acad. Sci. USA 105 2008 13568 13573
112. T. Ohta, K. Iijima, M. Miyamoto, I. Nakahara, H. Tanaka, M. Ohtsuji, T. Suzuki, A. Kobayashi, J. Yokota, T. Sakiyama, T. Shibata, M. Yamamoto, and S. Hirohashi Loss of Keap1 function activates Nrf2 and provides advantages for lung cancer cell growth Cancer Res. 68 2008 1303 1309 (Pubitemid 351346836)
113. L.M. Solis, C. Behrens, W. Dong, M. Suraokar, N.C. Ozburn, C.A. Moran, A.H. Corvalan, S. Biswal, S.G. Swisher, B.N. Bekele, J.D. Minna, D.J. Stewart, and I.I. Wistuba Nrf2 and Keap1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic features Clin. Cancer Res. 16 2010 3743 3753
114. P.A. Konstantinopoulos, D. Spentzos, E. Fountzilas, N. Francoeur, S. Sanisetty, A.P. Grammatikos, J.L. Hecht, and S.A. Cannistra Keap1 mutations and Nrf2 pathway activation in epithelial ovarian cancer Cancer Res. 71 2011 5081 5089
115. X.J. Wang, Z. Sun, N.F. Villeneuve, S. Zhang, F. Zhao, Y. Li, W. Chen, X. Yi, W. Zheng, G.T. Wondrak, P.K. Wong, and D.D. Zhang Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2 Carcinogenesis 29 2008 1235 1243 (Pubitemid 351958704)
116. G.S. Shim, S. Manandhar, D.H. Shin, T.H. Kim, and M.K. Kwak Acquisition of doxorubicin resistance in ovarian carcinoma cells accompanies activation of the NRF2 pathway Free Radic. Biol. Med. 47 2009 1619 1631
117. X. Ma, J. Zhang, S. Liu, Y. Huang, B. Chen, and D. Wang Nrf2 knockdown by shRNA inhibits tumor growth and increases efficacy of chemotherapy in cervical cancer Cancer Chemother. Pharmacol. 69 2012 485 494
118. Zhong, Y.; Zhang, F.; Sun, Z.; Zhou, W.; Li, Z. Y.; You, Q. D.; Guo, Q. L.; Hu, R. Drug resistance associates with activation of Nrf2 in MCF-7/DOX cells, and wogonin reverses it by down-regulating Nrf2-mediated cellular defense response. Mol. Carcinog. (in press). 10.1002/mc.21921
119. Y. Hu, W. Lu, G. Chen, H. Zhang, Y. Jia, Y. Wei, H. Yang, W. Zhang, W. Fiskus, K. Bhalla, M. Keating, P. Huang, and G. Garcia-Manero Overcoming resistance to histone deacetylase inhibitors in human leukemia with the redox modulating compound beta-phenylethyl isothiocyanate Blood 116 2010 2732 2741
120. T. Jiang, N. Chen, F. Zhao, X.J. Wang, B. Kong, W. Zheng, and D.D. Zhang High levels of Nrf2 determine chemoresistance in type II endometrial cancer Cancer Res. 70 2010 5486 5496
121. S.S. Syed Alwi, B.E. Cavell, A. Donlevy, and G. Packham Differential induction of apoptosis in human breast cancer cell lines by phenethyl isothiocyanate, a glutathione depleting agent Cell Stress Chaperones 17 2012 529 538
122. S. Manandhar, B.H. Choi, K.A. Jung, I.G. Ryoo, M. Song, S.J. Kang, H.G. Choi, J.A. Kim, P.H. Park, and M.K. Kwak NRF2 inhibition represses ErbB2 signaling in ovarian carcinoma cells: implications for tumor growth retardation and docetaxel sensitivity Free Radic. Biol. Med. 52 2012 1773 1785
123. J.M. Maher, M.Z. Dieter, L.M. Aleksunes, A.L. Slitt, G. Guo, Y. Tanaka, G.L. Scheffer, J.Y. Chan, J.E. Manautou, Y. Chen, T.P. Dalton, M. Yamamoto, and C.D. Klaassen Oxidative and electrophilic stress induces multidrug resistance-associated protein transporters via the nuclear factor-E2-related factor-2 transcriptional pathway Hepatology 46 2007 1597 1610 (Pubitemid 350155541)
124. C.M. Mahaffey, H. Zhang, A. Rinna, W. Holland, P.C. Mack, and H.J. Forman Multidrug-resistant protein-3 gene regulation by the transcription factor Nrf2 in human bronchial epithelial and non-small-cell lung carcinoma Free Radic. Biol. Med. 46 2009 1650 1657
125. H. Sasaki, M. Shitara, K. Yokota, Y. Hikosaka, S. Moriyama, M. Yano, and Y. Fujii MRP3 gene expression correlates with NRF2 mutations in lung squamous cell carcinomas Mol. Med. Rep 6 2012 705 708
126. B. Wang, X. Zhu, Y. Kim, J. Li, S. Huang, S. Saleem, R.C. Li, Y. Xu, S. Dore, and W. Cao Histone deacetylase inhibition activates transcription factor Nrf2 and protects against cerebral ischemic damage Free Radic. Biol. Med. 52 2012 928 936
127. S.K. Sahni, E. Rydkina, and A. Sahni The proteasome inhibitor MG132 induces nuclear translocation of erythroid transcription factor Nrf2 and cyclooxygenase-2 expression in human vascular endothelial cells Thromb. Res 122 2008 820 825
128. H. Dreger, K. Westphal, N. Wilck, G. Baumann, V. Stangl, K. Stangl, and S. Meiners Protection of vascular cells from oxidative stress by proteasome inhibition depends on Nrf2 Cardiovasc. Res. 85 2010 395 403
129. B. Ebert, M. Kisiela, V. Wsol, and E. Maser Proteasome inhibitors MG-132 and bortezomib induce AKR1C1, AKR1C3, AKR1B1, and AKR1B10 in human colon cancer cell lines SW-480 and HT-29 Chem. Biol. Interact. 191 2011 239 249
130. M.A. Weniger, E.G. Rizzatti, P. Perez-Galan, D. Liu, Q. Wang, P.J. Munson, N. Raghavachari, T. White, M.M. Tweito, K. Dunleavy, Y. Ye, W.H. Wilson, and A. Wiestner Treatment-induced oxidative stress and cellular antioxidant capacity determine response to bortezomib in mantle cell lymphoma Clin. Cancer Res. 17 2011 5101 5112
131. S.A. Rushworth, K.M. Bowles, and D.J. MacEwan High basal nuclear levels of Nrf2 in acute myeloid leukemia reduces sensitivity to proteasome inhibitors Cancer Res. 71 2011 1999 2009
132. Z.X. Du, Y. Yan, H.Y. Zhang, B.Q. Liu, Y.Y. Gao, X.F. Niu, X. Meng, and H.Q. Wang Proteasome inhibition induces a p38 MAPK pathway-dependent
133. Z.H. Zong, Z.X. Du, N. Li, C. Li, Q. Zhang, B.Q. Liu, Y. Guan, and H.Q. Wang Implication of Nrf2 and ATF4 in differential induction of CHOP by proteasome inhibition in thyroid cancer cells Biochim. Biophys. Acta 1823 2012 1395 1404
134. Y.H. Ling, L. Liebes, Y. Zou, and R. Perez-Soler Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells J. Biol. Chem 278 2003 33714 33723 (Pubitemid 37553204)
135. S. Lee, E.G. Hur, I.G. Ryoo, K.A. Jung, J. Kwak, and M.K. Kwak Involvement of the Nrf2-proteasome pathway in the endoplasmic reticulum stress response in pancreatic beta-cells Toxicol. Appl. Pharmacol. 264 2012 431 438
136. A.M. Pickering, R.A. Linder, H. Zhang, H.J. Forman, and K.J. Davies Nrf2-dependent induction of proteasome and Pa28alphabeta regulator are required for adaptation to oxidative stress J. Biol. Chem. 287 2012 10021 10031
137. D. Siegel, W.A. Franklin, and D. Ross Immunohistochemical detection of NAD(P)H:quinone oxidoreductase in human lung and lung tumors Clin. Cancer Res. 4 1998 2065 2070 (Pubitemid 28415648)
138. B. Padmanabhan, K.I. Tong, T. Ohta, Y. Nakamura, M. Scharlock, M. Ohtsuji, M.I. Kang, A. Kobayashi, S. Yokoyama, and M. Yamamoto Structural basis for defects of Keap1 activity provoked by its point mutations in lung cancer Mol. Cell 21 2006 689 700 (Pubitemid 43290735)
139. P. Nioi, and T. Nguyen A mutation of Keap1 found in breast cancer impairs its ability to repress Nrf2 activity Biochem. Biophys. Res. Commun 362 2007 816 821 (Pubitemid 47390646)
140. J.W. Kaspar, S.K. Niture, and A.K. Jaiswal Antioxidant-induced INrf2 (Keap1) tyrosine 85 phosphorylation controls the nuclear export and degradation of the INrf2-Cul3-Rbx1 complex to allow normal Nrf2 activation and repression J. Cell. Sci 125 2012 1027 1038
141. Q.K. Li, A. Singh, S. Biswal, F. Askin, and E. Gabrielson KEAP1 gene mutations and NRF2 activation are common in pulmonary papillary adenocarcinoma J. Hum. Genet. 56 2011 230 234
142. T. Takahashi, M. Sonobe, T. Menju, E. Nakayama, N. Mino, S. Iwakiri, S. Nagai, K. Sato, R. Miyahara, K. Okubo, T. Hirata, H. Date, and H. Wada Mutations in Keap1 are a potential prognostic factor in resected non-small cell lung cancer J. Surg. Oncol. 101 2010 500 506
143. Y.R. Kim, J.E. Oh, M.S. Kim, M.R. Kang, S.W. Park, J.Y. Han, H.S. Eom, N.J. Yoo, and S.H. Lee Oncogenic NRF2 mutations in squamous cell carcinomas of oesophagus and skin J. Pathol. 220 2010 446 451
144. T. Sjoblom, S. Jones, L.D. Wood, D.W. Parsons, J. Lin, T.D. Barber, D. Mandelker, R.J. Leary, J. Ptak, N. Silliman, S. Szabo, P. Buckhaults, C. Farrell, P. Meeh, S.D. Markowitz, J. Willis, D. Dawson, J.K. Willson, A.F. Gazdar, J. Hartigan, L. Wu, C. Liu, G. Parmigiani, B.H. Park, K.E. Bachman, N. Papadopoulos, B. Vogelstein, K.W. Kinzler, and V.E. Velculescu The consensus coding sequences of human breast and colorectal cancers Science 314 2006 268 274 (Pubitemid 44571966)
145. N.J. Yoo, H.R. Kim, Y.R. Kim, C.H. An, and S.H. Lee Somatic mutations of the KEAP1 gene in common solid cancers Histopathology 60 2012 943 952
146. P. Zhang, A. Singh, S. Yegnasubramanian, D. Esopi, P. Kombairaju, M. Bodas, H. Wu, S.G. Bova, and S. Biswal Loss of kelch-like ECH-associated protein 1 function in prostate cancer cells causes chemoresistance and radioresistance and promotes tumor growth Mol. Cancer. Ther 9 2010 336 346
147. S. Lee, M.J. Lim, M.H. Kim, C.H. Yu, Y.S. Yun, J. Ahn, and J.Y. Song An effective strategy for increasing the radiosensitivity of human lung cancer cells by blocking Nrf2-dependent antioxidant responses Free Radic. Biol. Med. 53 2012 807 816
148. S.A. Rushworth, L. Zaitseva, M.Y. Murray, N.M. Shah, K.M. Bowles, and D.J. MacEwan The high Nrf2 expression in human acute myeloid leukemia is driven by NF-kappaB and underlies its chemo-resistance Blood 120 2012 5188 5198
149. M.K. Kwak, K. Itoh, M. Yamamoto, T.R. Sutter, and T.W. Kensler Role of transcription factor Nrf2 in the induction of hepatic phase 2 and antioxidative enzymes in vivo by the cancer chemoprotective agent, 3H-1,2-dimethiole-3-thione Mol. Med 7 2001 135 145 (Pubitemid 33702029)
150. G. Garcia-Manero, F.P. Tambaro, N.B. Bekele, H. Yang, F. Ravandi, E. Jabbour, G. Borthakur, T.M. Kadia, M.Y. Konopleva, S. Faderl, J.E. Cortes, M. Brandt, Y. Hu, D. McCue, W.M. Newsome, and S.R. Pierce de Lima, M.; Kantarjian, H. M. Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome J. Clin. Oncol. 30 2012 2204 2210
151. E.M. Je, C.H. An, N.J. Yoo, and S.H. Lee Mutational and expressional analyses of NRF2 and KEAP1 in sarcomas Tumori 98 2012 510 515
152. A.K. Jaiswal Jun and fos regulation of NAD(P)H:quinone oxidoreductase gene expression Pharmacogenetics 4 1994 1 10 (Pubitemid 24106118)
153. R. Yu, C. Chen, Y.Y. Mo, V. Hebbar, E.D. Owuor, T.H. Tan, and A.N. Kong Activation of mitogen-activated protein kinase pathways induces antioxidant response element-mediated gene expression via a Nrf2-dependent mechanism J. Biol. Chem. 275 2000 39907 39913 (Pubitemid 32064611)
154. S.B. Cullinan, D. Zhang, M. Hannink, E. Arvisais, R.J. Kaufman, and J.A. Diehl Nrf2 is a direct PERK substrate and effector of PERK-dependent cell survival Mol. Cell. Biol. 23 2003 7198 7209 (Pubitemid 37211002)
155. S. Papaiahgari, S.R. Kleeberger, H.Y. Cho, D.V. Kalvakolanu, and S.P. Reddy NADPH oxidase and ERK signaling regulates hyperoxia-induced Nrf2-ARE transcriptional response in pulmonary epithelial cells J. Biol. Chem. 279 2004 42302 42312 (Pubitemid 39313679)
156. G. Shen, V. Hebbar, S. Nair, C. Xu, W. Li, W. Lin, Y.S. Keum, J. Han, M.A. Gallo, and A.N. Kong Regulation of Nrf2 transactivation domain activity: the differential effects of mitogen-activated protein kinase cascades and synergistic stimulatory effect of raf and CREB-binding protein J. Biol. Chem. 279 2004 23052 23060 (Pubitemid 38685609)
157. C. Xu, X. Yuan, Z. Pan, G. Shen, J.H. Kim, S. Yu, T.O. Khor, W. Li, J. Ma, and A.N. Kong Mechanism of action of isothiocyanates: the induction of ARE-regulated genes is associated with activation of ERK and JNK and the phosphorylation and nuclear translocation of Nrf2 Mol. Cancer. Ther 5 2006 1918 1926 (Pubitemid 44336562)
158. X. Yuan, C. Xu, Z. Pan, Y.S. Keum, J.H. Kim, G. Shen, S. Yu, K.T. Oo, J. Ma, and A.N. Kong Butylated hydroxyanisole regulates ARE-mediated gene expression via Nrf2 coupled with ERK and JNK signaling pathway in HepG2 cells Mol. Carcinog. 45 2006 841 850 (Pubitemid 44646336)
159. K.C. Kim, K.A. Kang, R. Zhang, M.J. Piao, G.Y. Kim, M.Y. Kang, S.J. Lee, N.H. Lee, Y.J. Surh, and J.W. Hyun Up-regulation of Nrf2-mediated heme oxygenase-1 expression by eckol, a phlorotannin compound, through activation of erk and PI3K/akt Int. J. Biochem. Cell Biol. 42 2010 297 305
160. J.M. Lee, J.M. Hanson, W.A. Chu, and J.A. Johnson Phosphatidylinositol 3-kinase, not extracellular signal-regulated kinase, regulates activation of the antioxidant-responsive element in IMR-32 human neuroblastoma cells J. Biol. Chem. 276 2001 20011 20016
161. H.C. Huang, T. Nguyen, and C.B. Pickett Phosphorylation of Nrf2 at ser-40 by protein kinase C regulates antioxidant response element-mediated transcription J. Biol. Chem. 277 2002 42769 42774 (Pubitemid 35285650)
162. D.A. Bloom, and A.K. Jaiswal Phosphorylation of Nrf2 at Ser40 by protein kinase C in response to antioxidants leads to the release of Nrf2 from INrf2, but is not required for Nrf2 stabilization/accumulation in the nucleus and transcriptional activation of antioxidant response element-mediated NAD(P)H:quinone oxidoreductase-1 gene expression J. Biol. Chem 278 2003 44675 44682 (Pubitemid 37377224)
163. R. Yu, S. Mandlekar, W. Lei, W.E. Fahl, T.H. Tan, and A.N. Kong p38 mitogen-activated protein kinase negatively regulates the induction of phase II drug-metabolizing enzymes that detoxify carcinogens J. Biol. Chem. 275 2000 2322 2327 (Pubitemid 30081988)
164. Y.S. Keum, S. Yu, P.P. Chang, X. Yuan, J.H. Kim, C. Xu, J. Han, A. Agarwal, and A.N. Kong Mechanism of action of sulforaphane: inhibition of p38 mitogen-activated protein kinase isoforms contributing to the induction of antioxidant response element-mediated heme oxygenase-1 in human hepatoma HepG2 cells Cancer Res. 66 2006 8804 8813 (Pubitemid 44449198)
165. M. Salazar, A.I. Rojo, and D. Velasco de Sagarra, R. M.; Cuadrado, A. Glycogen synthase kinase-3beta inhibits the xenobiotic and antioxidant cell response by direct phosphorylation and nuclear exclusion of the transcription factor Nrf2 J. Biol. Chem 281 2006 14841 14851 (Pubitemid 43855189)
166. A.K. Jain, and A.K. Jaiswal GSK-3beta acts upstream of fyn kinase in regulation of nuclear export and degradation of NF-E2 related factor 2 J. Biol. Chem 282 2007 16502 16510 (Pubitemid 47100395)
167. K. Sakamoto, K. Iwasaki, H. Sugiyama, and Y. Tsuji Role of the tumor suppressor PTEN in antioxidant responsive element-mediated transcription and associated histone modifications Mol. Biol. Cell 20 2009 1606 1617
168. N. Chen, X. Yi, N. Abushahin, S. Pang, D. Zhang, B. Kong, and W. Zheng Nrf2 expression in endometrial serous carcinomas and its precancers Int. J. Clin. Exp. Pathol. 4 2010 85 96
169. H. Liao, Q. Zhou, Z. Zhang, Q. Wang, Y. Sun, X. Yi, and Y. Feng NRF2 is overexpressed in ovarian epithelial carcinoma and is regulated by gonadotrophin and sex-steroid hormones Oncol. Rep. 27 2012 1918 1924
170. V. Okoh, A. Deoraj, and D. Roy Estrogen-induced reactive oxygen species-mediated signalings contribute to breast cancer Biochim. Biophys. Acta 1815 2011 115 133
171. B. Singh, and H.K. Bhat Superoxide dismutase 3 is induced by antioxidants, inhibits oxidative DNA damage and is associated with inhibition of estrogen-induced breast cancer Carcinogenesis 33 2012 2601 2610
172. M. Loignon, W. Miao, L. Hu, A. Bier, T.A. Bismar, P.J. Scrivens, K. Mann, M. Basik, A. Bouchard, P.O. Fiset, Z. Batist, and G. Batist Cul3 overexpression depletes Nrf2 in breast cancer and is associated with sensitivity to carcinogens, to oxidative stress, and to chemotherapy Mol. Cancer. Ther 8 2009 2432 2440
173. G. Eades, M. Yang, Y. Yao, Y. Zhang, and Q. Zhou miR-200a regulates Nrf2 activation by targeting Keap1 mRNA in breast cancer cells J. Biol. Chem. 286 2011 40725 40733
174. A. Jain, T. Lamark, E. Sjottem, K.B. Larsen, J.A. Awuh, A. Overvatn, M. McMahon, J.D. Hayes, and T. Johansen p62/SQSTM1 is a target gene for transcription factor NRF2 and creates a positive feedback loop by inducing antioxidant response element-driven gene transcription J. Biol. Chem. 285 2010 22576 22591
175. S. Pankiv, T.H. Clausen, T. Lamark, A. Brech, J.A. Bruun, H. Outzen, A. Overvatn, G. Bjorkoy, and T. Johansen p62/SQSTM1 binds directly to Atg8/LC3 to facilitate degradation of ubiquitinated protein aggregates by autophagy J. Biol. Chem. 282 2007 24131 24145 (Pubitemid 47328003)
176. M. Komatsu, H. Kurokawa, S. Waguri, K. Taguchi, A. Kobayashi, Y. Ichimura, Y.S. Sou, I. Ueno, A. Sakamoto, K.I. Tong, M. Kim, Y. Nishito, S. Iemura, T. Natsume, T. Ueno, E. Kominami, H. Motohashi, K. Tanaka, and M. Yamamoto The selective autophagy substrate p62 activates the stress responsive transcription factor Nrf2 through inactivation of Keap1 Nat. Cell Biol. 12 2010 213 223
177. M. Komatsu, S. Waguri, M. Koike, Y.S. Sou, T. Ueno, T. Hara, N. Mizushima, J. Iwata, J. Ezaki, S. Murata, J. Hamazaki, Y. Nishito, S. Iemura, T. Natsume, T. Yanagawa, J. Uwayama, E. Warabi, H. Yoshida, T. Ishii, A. Kobayashi, M. Yamamoto, Z. Yue, Y. Uchiyama, E. Kominami, and K. Tanaka Homeostatic levels of p62 control cytoplasmic inclusion body formation in autophagy-deficient mice Cell 131 2007 1149 1163 (Pubitemid 350235021)
178. Y. Inami, S. Waguri, A. Sakamoto, T. Kouno, K. Nakada, O. Hino, S. Watanabe, J. Ando, M. Iwadate, M. Yamamoto, M.S. Lee, K. Tanaka, and M. Komatsu Persistent activation of Nrf2 through p62 in hepatocellular carcinoma cells J. Cell Biol. 193 2011 275 284
179. M. Lu, R.M. Nakamura, E.D. Dent, J.Y. Zhang, F.C. Nielsen, J. Christiansen, E.K. Chan, and E.M. Tan Aberrant expression of fetal RNA-binding protein p62 in liver cancer and liver cirrhosis Am. J. Pathol. 159 2001 945 953 (Pubitemid 32847185)
180. K. Zatloukal, C. Stumptner, A. Fuchsbichler, H. Heid, M. Schnoelzer, L. Kenner, R. Kleinert, M. Prinz, A. Aguzzi, and H. Denk p62 is a common component of cytoplasmic inclusions in protein aggregation diseases Am. J. Pathol. 160 2002 255 263 (Pubitemid 34052286)
181. G.O. Kisen, L. Tessitore, P. Costelli, P.B. Gordon, P.E. Schwarze, F.M. Baccino, and P.O. Seglen Reduced autophagic activity in primary rat hepatocellular carcinoma and ascites hepatoma cells Carcinogenesis 14 1993 2501 2505 (Pubitemid 24016585)
182. M. Komatsu Potential role of p62 in tumor development Autophagy 7 2011 1088 1090
183. A. Duran, J.F. Linares, A.S. Galvez, K. Wikenheiser, J.M. Flores, M.T. Diaz-Meco, and J. Moscat The signaling adaptor p62 is an important NF-kappaB mediator in tumorigenesis Cancer Cell 13 2008 343 354 (Pubitemid 351446193)
184. R. Mathew, C.M. Karp, B. Beaudoin, N. Vuong, G. Chen, H.Y. Chen, K. Bray, A. Reddy, G. Bhanot, C. Gelinas, R.S. Dipaola, V. Karantza-Wadsworth, and E. White Autophagy suppresses tumorigenesis through elimination of p62 Cell 137 2009 1062 1075
185. Z. Jin, Y. Li, R. Pitti, D. Lawrence, V.C. Pham, J.R. Lill, and A. Ashkenazi Cullin3-based polyubiquitination and p62-dependent aggregation of caspase-8 mediate extrinsic apoptosis signaling Cell 137 2009 721 735
186. K. Bray, R. Mathew, A. Lau, J.J. Kamphorst, J. Fan, J. Chen, H.Y. Chen, A. Ghavami, M. Stein, R.S. DiPaola, D. Zhang, J.D. Rabinowitz, and E. White Autophagy suppresses RIP kinase-dependent necrosis enabling survival to mTOR inhibition PLoS One 7 2012 e41831
187. E. Morselli, L. Galluzzi, O. Kepp, J.M. Vicencio, A. Criollo, M.C. Maiuri, and G. Kroemer Anti- and pro-tumor functions of autophagy Biochim. Biophys. Acta 1793 2009 1524 1532
188. D. Inoue, T. Suzuki, Y. Mitsuishi, Y. Miki, S. Suzuki, S. Sugawara, M. Watanabe, A. Sakurada, C. Endo, A. Uruno, H. Sasano, T. Nakagawa, K. Satoh, N. Tanaka, H. Kubo, H. Motohashi, and M. Yamamoto Accumulation of p62/SQSTM1 is associated with poor prognosis in patients with lung adenocarcinoma Cancer. Sci. 103 2012 760 766
189. R. Wang, J. An, F. Ji, H. Jiao, H. Sun, and D. Zhou Hypermethylation of the Keap1 gene in human lung cancer cell lines and lung cancer tissues Biochem. Biophys. Res. Commun. 373 2008 151 154
190. L.A. Muscarella, P. Parrella, V. D'Alessandro, A. la Torre, R. Barbano, A. Fontana, A. Tancredi, V. Guarnieri, T. Balsamo, M. Coco, M. Copetti, F. Pellegrini, P. De Bonis, M. Bisceglia, G. Scaramuzzi, E. Maiello, V.M. Valori, G. Merla, G. Vendemiale, and V.M. Fazio Frequent epigenetics inactivation of KEAP1 gene in non-small cell lung cancer Epigenetics 6 2011 710 719
191. L.A. Muscarella, R. Barbano, V. D'Angelo, M. Copetti, M. Coco, T. Balsamo, A. la Torre, A. Notarangelo, M. Troiano, S. Parisi, N. Icolaro, D. Catapano, V.M. Valori, F. Pellegrini, G. Merla, M. Carella, V.M. Fazio, and P. Parrella Regulation of KEAP1 expression by promoter methylation in malignant gliomas and association with patient's outcome Epigenetics 6 2011 317 325
192. M. Esteller, J. Garcia-Foncillas, E. Andion, S.N. Goodman, O.F. Hidalgo, V. Vanaclocha, S.B. Baylin, and J.G. Herman Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents N. Engl. J. Med. 343 2000 1350 1354
193. N. Hanada, T. Takahata, Q. Zhou, X. Ye, R. Sun, J. Itoh, A. Ishiguro, H. Kijima, J. Mimura, K. Itoh, S. Fukuda, and Y. Saijo Methylation of the KEAP1 gene promoter region in human colorectal cancer BMC Cancer 12 2012 66
194. S. Yu, T.O. Khor, K.L. Cheung, W. Li, T.Y. Wu, Y. Huang, B.A. Foster, Y.W. Kan, and A.N. Kong Nrf2 expression is regulated by epigenetic mechanisms in prostate cancer of TRAMP mice PLoS One 5 2010 e8579
195. Z. Sun, Y.E. Chin, and D.D. Zhang Acetylation of Nrf2 by p300/CBP augments promoter-specific DNA binding of Nrf2 during the antioxidant response Mol. Cell. Biol. 29 2009 2658 2672
196. Y. Kawai, L. Garduno, M. Theodore, J. Yang, and I.J. Arinze Acetylation-deacetylation of the transcription factor Nrf2 (nuclear factor erythroid 2-related factor 2) regulates its transcriptional activity and nucleocytoplasmic localization J. Biol. Chem. 286 2011 7629 7640
197. N. Mercado, R. Thimmulappa, C.M. Thomas, P.S. Fenwick, K.K. Chana, L.E. Donnelly, S. Biswal, K. Ito, and P.J. Barnes Decreased histone deacetylase 2 impairs Nrf2 activation by oxidative stress Biochem. Biophys. Res. Commun. 406 2011 292 298
198. K.A. Jung, B.H. Choi, C.W. Nam, M. Song, S.T. Kim, J.Y. Lee, and M.K. Kwak Identification of aldo-keto reductases as NRF2-target marker genes in human cells Toxicol. Lett. 218 2013 39 49
199. W.J. Blot, J.Y. Li, P.R. Taylor, W. Guo, S. Dawsey, G.Q. Wang, C.S. Yang, S.F. Zheng, M. Gail, and G.Y. Li Nutrition intervention trials in Linxian, China: supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population J. Natl. Cancer Inst. 85 1993 1483 1492 (Pubitemid 23269183)
200. Y.L. Qiao, S.M. Dawsey, F. Kamangar, J.H. Fan, C.C. Abnet, X.D. Sun, L.L. Johnson, M.H. Gail, Z.W. Dong, B. Yu, S.D. Mark, and P.R. Taylor Total and cancer mortality after supplementation with vitamins and minerals: follow-up of the Linxian General Population Nutrition Intervention Trial J. Natl. Cancer Inst. 101 2009 507 518
201. T.W. Kensler, and N. Wakabayashi Nrf2: friend or foe for chemoprevention? Carcinogenesis 31 2010 90 99
202. D. Ren, N.F. Villeneuve, T. Jiang, T. Wu, A. Lau, H.A. Toppin, and D.D. Zhang Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism Proc. Natl. Acad. Sci. USA 108 2011 1433 1438
203. I. Bobilev, V. Novik, I. Levi, O. Shpilberg, J. Levy, Y. Sharoni, G.P. Studzinski, and M. Danilenko The Nrf2 transcription factor is a positive regulator of myeloid differentiation of acute myeloid leukemia cells Cancer. Biol. Ther. 11 2011 317 329
204. L. Zhan, H. Zhang, Q. Zhang, C.G. Woods, Y. Chen, P. Xue, J. Dong, E.J. Tokar, Y. Xu, Y. Hou, J. Fu, K. Yarborough, A. Wang, W. Qu, M.P. Waalkes, M.E. Andersen, and J. Pi Regulatory role of KEAP1 and NRF2 in PPARγ expression and chemoresistance in human non-small-cell lung carcinoma cells Free Radic. Biol. Med. 53 2012 758 768